Email updates

Keep up to date with the latest news and content from JNI and BioMed Central.

Open Access Highly Accessed Commentary

Luteolin as a therapeutic option for multiple sclerosis

Theoharis C Theoharides

Author Affiliations

Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center, Boston, MA, USA

Department of Internal Medicine, Biochemistry and Psychiatry, Tufts University School of Medicine and Tufts Medical Center, Boston, MA, USA

Journal of Neuroinflammation 2009, 6:29  doi:10.1186/1742-2094-6-29


The electronic version of this article is the complete one and can be found online at: http://www.jneuroinflammation.com/content/6/1/29


Received:31 July 2009
Accepted:13 October 2009
Published:13 October 2009

© 2009 Theoharides; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Multiple sclerosis (MS) remains without an effective treatment in spite of intense research efforts. Interferon-beta (IFN-β) reduces duration and severity of symptoms in many relapsing-remitting MS patients, but its mechanism of action is still not well understood. Moreover, IFN-β and other available treatments must be given parenterally and have a variety of adverse effects. Certain naturally occurring flavonoids, such as luteolin, have anti-oxidant and anti-inflammatory effects, including inhibition of activated peripheral blood leukocytes from MS patients. Luteolin also inhibits mast cells, as well as mast cell-dependent T cell activation, recently implicated in MS pathogenesis. Moreover, luteolin and structurally similar flavonoids can inhibit experimental allergic allergic encephalomyelitis (EAE), an animal model of MS in rodents. An appropriate luteolin formulation that permits sufficient absorption and reduces its metabolism could be a useful adjuvant to IFN-β for MS therapy.

Introduction

This issue includes an interesting article by Sternberg et al. showing that the flavonoid luteolin inhibits IL-1, TNF and metalloproteinase-9 (MMP-9) release from activated peripheral blood mononuclear cells (PBMCs) from multiple sclerosis (MS) patients, and that the effect of luteolin is augmented by concurrent administration of interferon-beta (IFN-β). This paper extends previous similar results with quercetin that required higher concentrations of the flavonoid [1].

Discussion

Luteolin with or without IFN-β, could be helpful in MS by not only inhibiting PBMC release of cytokines, but also by inhibiting T cells, which we recently showed can be superstimulated by mast cells, an action also inhibited by luteolin [2]. In addition to T cells, recent evidence implicates also TH2 processes typically associated with allergic reactions [3-5], which involve mast cells (Fig. 1). In fact, mast cells have been considered as the next target for MS therapy [6-8].

thumbnailFigure 1. Diagrammatic representation of the inhibitory effect of luteolin on brain mast cells and infiltrating monocytes in the pathogenesis of multiple sclerosis.

Brain MS plaques also contain activated mast cells [9,10], which have been associated with brain demyelination [11-13]. Gene array analysis also showed that MS plaques had increased gene expression for the IgE receptor (FcεRI), the histamine-1 receptor and the protease tryptase, all of which are associated with mast cells [14-16]. Mast cell tryptase is elevated in the CSF of MS patients [17], can activate peripheral mononuclear cells to secrete TNF and IL-6 [18], as well as stimulate protease-activated receptors (PAR) to induce widespread inflammation [19]. Brain mast cells can secrete TNF [20], which is involved in both brain inflammation [21] and blood-brain-barrier (BBB) permeability [22]. In fact, BBB disruption precedes any pathologic signs of MS [23] and mast cells can disrupt the BBB [24,25].

Flavonoids such as quercetin have potent anti-oxidant and anti-inflammatory activity [26]. Quercetin and luteolin also inhibit human cultured mast cell release of histamine, leukotrienes and prostaglandin D2 [27], as well as IL-6, IL-8, TNF-α and tryptase [28,29]. Moreover, quercetin and luteolin inhibit mast cell activation stimulated by IL-1 [30] leading to selective release of IL-6. Luteolin also inhibits IL-6 release from microglia cells [31], and from astrocytes [32]. Flavonoids can also inhibit myelin phagocytosis by macrophages [33], as well as inhibit EAE [34-36].

Conclusion

Quercetin and its structurally related luteolin are safe [37]. The fact remains that less than 10% of flavonoids are absorbed orally [37]. Novel ways of delivering select flavonoid combinations would be required to assure sufficient plasma levels, especially if luteolin were to also inhibit brain inflammation. Such a test nutraceutical formulation has already been tried on a number of relapsing-remitting MS patients treated with INF-β with encouraging positive results.

Competing interests

TCT has been awarded US patents No 6,689,748; 6,984,667 and EPO No 1365777 that cover the use of flavonoids in inflammatory diseases; he has also filed (3/30/04) US patent applications No. 10/811,826; 11/214,831; 11/999,991; 12/151,268 specifically covering combinations of flavonoids, including luteolin with INF-β, for the treatment of MS.

References

  1. Sternberg Z, Chadha K, Lieberman A, Hojnacki D, Drake A, Zamboni P, Rocco P, Grazioli E, Weinstock-Guttman B, Munschauer F: Quercetin and interferon-beta modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients.

    J Neuroimmunol 2008, 205:142-147. PubMed Abstract | Publisher Full Text OpenURL

  2. Kempuraj D, Tagen M, Iliopoulou BP, Clemons A, Vasiadi M, Boucher W, House M, Wolfberg A, Theoharides TC: Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell dependent stimulation of Jurkat T cells.

    Br J Pharmacol 2008, 155:1076-1084. PubMed Abstract | Publisher Full Text OpenURL

  3. Robbie-Ryan M, Tanzola MB, Secor VH, Brown MA: Cutting edge: both activating and inhibitory Fc receptors expressed on mast cells regulate experimental allergic encephalomyelitis disease severity.

    J Immunol 2003, 170:1630-1634. PubMed Abstract | Publisher Full Text OpenURL

  4. Pedotti R, De Voss JJ, Steinman L, Galli SJ: Involvement of both 'allergic' and 'autoimmune' mechanisms in EAE, MS and other autoimmune diseases.

    Trends Immunol 2003, 24:479-484. PubMed Abstract | Publisher Full Text OpenURL

  5. Pedotti R, DeVoss JJ, Youssef S, Mitchell D, Wedemeyer J, Madanat R, Garren H, Fontoura P, Tsai M, Galli SJ, Sobel RA, Steinman L: Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination.

    Proc Natl Acad Sci USA 2003, 100:1867-1872. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  6. Theoharides TC: Mast cells: the immune gate to the brain.

    Life Sci 1990, 46:607-617. PubMed Abstract | Publisher Full Text OpenURL

  7. Zappulla JP, Arock M, Mars LT, Liblau RS: Mast cells: new targets for multiple sclerosis therapy?

    J Neuroimmunol 2002, 131:5-20. PubMed Abstract | Publisher Full Text OpenURL

  8. Theoharides TC, Cochrane DE: Critical role of mast cells in inflammatory diseases and the effect of acute stress.

    J Neuroimmunol 2004, 146:1-12. PubMed Abstract | Publisher Full Text OpenURL

  9. Olsson Y: Mast cells in plaques of multiple sclerosis.

    Acta Neurol Scand 1974, 50:611-618. PubMed Abstract OpenURL

  10. Krüger PG, Bø L, Myhr KM, Karlsen AE, Taule A, Nyland HI, Mørk S: Mast cells and multiple sclerosis: a light and electron microscopic study of mast cells in multiple sclerosis emphasizing staining procedures.

    Acta Neurol Scand 1990, 81:31-36. PubMed Abstract OpenURL

  11. Dietsch GN, Hinrichs DJ: The role of mast cells in the elicitation of experimental allergic encephalomyelitis.

    J Immunol 1989, 142:1476-1481. PubMed Abstract | Publisher Full Text OpenURL

  12. Johnson D, Seeldrayers PA, Weiner HL: The role of mast cells in demyelination. 1. Myelin proteins are degraded by mast cell proteases and myelin basic protein and P2 can stimulate mast cell degranulation.

    Brain Res 1988, 444:195-198. PubMed Abstract | Publisher Full Text OpenURL

  13. Theoharides TC, Dimitriadou V, Letourneau RJ, Rozniecki JJ, Vliagoftis H, Boucher WS: Synergistic action of estradiol and myelin basic protein on mast cell secretion and brain demyelination: changes resembling early stages of demyelination.

    Neuroscience 1993, 57:861-871. PubMed Abstract | Publisher Full Text OpenURL

  14. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L: Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis.

    Nat Med 2002, 8:500-508. PubMed Abstract | Publisher Full Text OpenURL

  15. Bomprezzi R, Ringnér M, Kim S, Bittner ML, Khan J, Chen Y, Elkahloun A, Yu A, Bielekova B, Meltzer PS, Martin R, McFarland HF, Trent JM: Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease.

    Hum Mol Genet 2003, 12:2191-2199. PubMed Abstract | Publisher Full Text OpenURL

  16. De Jager PL, Hafler DA: Gene expression profiling in MS: what is the clinical relevance?

    Lancet Neurol 2004, 3:269. PubMed Abstract | Publisher Full Text OpenURL

  17. Rozniecki JJ, Hauser SL, Stein M, Lincoln R, Theoharides TC: Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients.

    Ann Neurol 1995, 37:63-66. PubMed Abstract | Publisher Full Text OpenURL

  18. Malamud V, Vaaknin A, Abramsky O, Mor M, Burgess LE, Ben-Yehudah A, Lorberboum-Galski H: Tryptase activates peripheral blood mononuclear cells causing the synthesis and release of TNF-alpha, IL-6 and IL-1 beta: possible relevance to multiple sclerosis.

    J Neuoimmunol 2003, 138:115-122. Publisher Full Text OpenURL

  19. Molino M, Barnathan ES, Numerof R, Clark J, Dreyer M, Cumashi A, Hoxie JA, Schechter N, Woolkalis M, Brass LF: Interactions of mast cell tryptase with thrombin receptors and PAR-2.

    J Biol Chem 1997, 272:4043-4049. PubMed Abstract | Publisher Full Text OpenURL

  20. Cocchiara R, Bongiovanni A, Albeggiani G, Azzolina A, Geraci D: Evidence that brain mast cells can modulate neuroinflammatory responses by tumor necrosis factor-α production.

    Neuroreport 1998, 9:95-98. PubMed Abstract | Publisher Full Text OpenURL

  21. Probert L, Akassoglou K, Kassiotis G, Pasparakis M, Alexopoulou L, Kollias G: TNF-α transgenic and knockout models of CNS inflammation and degeneration.

    J Neuroimmunol 1997, 72:137-141. PubMed Abstract | Publisher Full Text OpenURL

  22. Kim KS, Wass CA, Cross AS, Opal SM: Modulation of blood-brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat.

    Lymphokine Cytokine Res 1992, 11:293-298. PubMed Abstract OpenURL

  23. Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DP, Moseley IF, Rudge P, McDonald WI: Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis.

    Brain 1990, 113:1477-1489. PubMed Abstract | Publisher Full Text OpenURL

  24. Esposito P, Chandler N, Kandere K, Basu S, Jacobson S, Connolly R, Tutor D, Theoharides TC: Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress.

    J Pharmacol Exp Ther 2002, 303:1061-1066. PubMed Abstract | Publisher Full Text OpenURL

  25. Esposito P, Gheorghe D, Kandere K, Pang X, Connolly R, Jacobson S, Theoharides TC: Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells.

    Brain Res 2001, 888:117-127. PubMed Abstract | Publisher Full Text OpenURL

  26. Middleton E Jr, Kandaswami C, Theoharides TC: The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer.

    Pharmacol Rev 2000, 52:673-751. PubMed Abstract | Publisher Full Text OpenURL

  27. Kimata M, Shichijo M, Miura T, Serizawa I, Inagaki N, Nagai H: Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells.

    Clin Exp Allergy 2000, 30:501-508. PubMed Abstract | Publisher Full Text OpenURL

  28. Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J, Papadopoulou N, Cetrulo CL, Theoharides TC: Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells.

    Br J Pharmacol 2005, 145:934-944. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  29. Park HH, Lee S, Son HY, Park SB, Kim MS, Choi EJ, Singh TS, Ha JH, Lee MG, Kim JE, Hyun MC, Kwon TK, Kim YH, Kim SH: Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells.

    Arch Pharm Res 2008, 31:1303-1311. PubMed Abstract | Publisher Full Text OpenURL

  30. Kandere-Grzybowska K, Kempuraj D, Cao J, Cetrulo CL, Theoharides TC: Regulation of IL-1-induced selective IL-6 release from human mast cells and inhibition by quercetin.

    Br J Pharmacol 2006, 148:208-215. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  31. Jang S, Kelley KW, Johnson RW: Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1.

    Proc Natl Acad Sci USA 2008, 105:7534-7539. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  32. Sharma V, Mishra M, Ghosh S, Tewari R, Basu A, Seth P, Sen E: Modulation of interleukin-1beta mediated inflammatory response in human astrocytes by flavonoids: implications in neuroprotection.

    Brain Res Bull 2007, 73:55-63. PubMed Abstract | Publisher Full Text OpenURL

  33. Hendriks JJ, de Vries HE, Pol SM, Berg TK, van Tol EA, Dijkstra CD: Flavonoids inhibit myelin phagocytosis by macrophages; a structure-activity relationship study.

    Biochem Pharmacol 2003, 65:877-885. PubMed Abstract | Publisher Full Text OpenURL

  34. Aktas O, Prozorovski T, Smorodchenko A, Savaskan NE, Lauster R, Kloetzel PM, Infante-Duarte C, Brocke S, Zipp F: Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis.

    J Immunol 2004, 173:5794-5800. PubMed Abstract | Publisher Full Text OpenURL

  35. Muthian G, Bright JJ: Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte.

    J Clin Immunol 2004, 24:542-552. PubMed Abstract | Publisher Full Text OpenURL

  36. Hendriks JJ, Alblas J, Pol SM, van Tol EA, Dijkstra CD, de Vries HE: Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis.

    J Exp Med 2004, 200:1667-1672. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  37. Manach C, Donovan JL: Pharmacokinetics and metabolism of dietary flavonoids in humans.

    Free Radic Res 2004, 38:771-785. PubMed Abstract | Publisher Full Text OpenURL